5-(5-bromo-6-methoxypyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 5-(5-bromo-6-methoxypyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2(3H)-one
• 英文别名: 5-(5-Bromo-6-methoxypyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2-one；5-(5-bromo-6-methoxypyridin-3-yl)-3-methyl-1,3,4-oxadiazol-2-one
• 化学式: C₉H₈BrN₃O₃
• 分子量: 286.085
• InChiKey: FZQHGQCNRWDCFV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  64
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• [EN] SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS<br/>[FR] COMPOSÉS SUBSTITUÉS DE PYRIDINE EN TANT QUE MODULATEURS DE CRAC
  申请人：LUPIN LTD

  公开号：WO2013164769A1

  公开（公告）日：2013-11-07

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release- activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I)and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及式(I)描述的化合物以及其中医药可接受的盐，这些化合物能够调节钙释放激活钙(CRAC)通道的活性。该发明还描述了式(I)的化合物以及包含这些化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关联的疾病、障碍、综合征或状况的严重性。
• SUBSTITUTED PYRIDINE COMPOUNDS AS CRAC MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20150111900A1

  公开（公告）日：2015-04-23

  The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.

  本发明涉及描述为公式(I)的化合物及其药用可接受盐，其调节钙释放激活钙(CRAC)通道的活性。本发明还描述了公式(I)的化合物及含有该化合物的药物组合物，用于治疗、管理和/或减轻与调节钙释放激活钙(CRAC)通道相关的疾病、疾病、综合征或病症的严重程度。
• US9399638B2
  申请人：——

  公开号：US9399638B2

  公开（公告）日：2016-07-26